Building an integrated biosimilars business

Published: 10.02.2020

In the latest issue of Business Trends, Hannes Teissl, Supervisory Board Member of Polpharma Biologics, highlights recently inked global commercialisation agreement with Sandoz AG for a natalizumab biosimilar for the treatment of relapsing-remitting multiple sclerosis (RRMS, affecting 85% of MS patients). He explains why the deal is a significant milestone for the company.

Read this article to learn what are the specifics of the agreement Polpharma Biologics has made with Sandoz AG. Learn more about the company's growth, expansion, manufacturing capacity and capabilities to fulfill this deal on a global scale.

“Polpharma Biologics is fully committed to provide more affordable quality biologics, which healthcare systems are in need of so much. Our specific dedication to deliver on quality, cost and supply is at the core of our strategy and is precisely why we have built a fully integrated biologics value chain. And we’re clearly in a growth market.“

Read full article here

written by: Polpharma Biologics

Let’s collaborate and create quality biologics together.

Get in touch for more information.

We use cookies

Polpharma Biologics uses cookies and other similar technologies (hereinafter: cookies) on its webpages and mobile applications (hereinafter, jointly, Website). The user can manage cookies independently by changing the web browser settings. If you do not consent for your personal data to be collected via cookies, you should change your web browser settings or stop using the Website.

Using the Website without changing the web browser settings indicates your acceptance of the use of cookies by Polpharma. Acceptance of the web browser settings indicates your consent to profiling on the basis of the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect lawfulness of any processing activities carried out under consent before its withdrawal.

For more details see the Cookie Policy.